399 - The evolution of Alzheimer's disease and dementia care | Gayatri Devi, M.D.
In a Nutshell
Dr. Gayatri Devi describes Alzheimer's as a heterogeneous spectrum driven by inflammation, amyloid, tau, and synaptic loss, with high-functioning patients often masking pathology for years through cognitive reserve. Early, personalized treatment using anti-amyloid monoclonal antibodies (lecanemab, donanemab), cholinesterase inhibitors, memantine, TMS, vascular risk control, and hormone therapy in appropriate women can meaningfully slow or stabilize disease, especially when started before advanced tau or synaptic damage. Diagnosis must combine biomarkers with clinical function rather than rely on blood tests alone, and mixed pathologies like vascular disease and Lewy bodies are the norm rather than exception.
These notes were generated by AI and may contain inaccuracies.
Dr. Gayatri Devi is a neurologist and psychiatrist boarded in multiple specialties including neurology, psychiatry, brain injury medicine, pain medicine, and behavioral neurology, with her subspecialty focus being memory disorders from a neurological perspective.
Two major shifts have occurred in Dr. Devi's understanding of dementing conditions over her career. First, all dementing conditions, particularly Alzheimer's disease, present variably depending on the individual and comorbidities, creating a spectrum aspect that many people fail to recognize. Dementias are not an all-or-nothing disease but span from very mild impairment that doesn't worsen to severe impairment that deteriorates rapidly. Second, the field is now at a transformative point where many different treatment approaches exist, allowing personalized medication combinations and disease-modifying drugs that can alter disease course.
Dementia is the umbrella term referring to loss of connectivity between brain cells resulting in loss of function as a progressive condition. Alzheimer's disease is the most common type and is defined as synaptic loss of connectivity driven by extra-neuronal amyloid plaques, intra-neuronal neurofibrillary tangles, and inflammation in supporting microglial cells and other glial cells of the brain substrate. Diagnosis is challenging because high-functioning, intelligent individuals with good brain reserve can compensate effectively and maintain performance despite moderate or even severe pathology.
Subtypes of Alzheimer's Disease
Alzheimer's disease subtypes depend on which brain region the pathology predominantly affects. Memory-predominant Alzheimer's differs from visual-spatial predominant forms. Comorbid brain conditions such as Lewy body disease, TDP43 pathology, or hippocampal sclerosis inform how the disease presents in each person.
Diagnostic Approaches
Two schools of thought exist regarding diagnosis. One group maintains that biological biomarkers alone suffice for diagnosis. The other requires biomarkers plus clinical symptoms and functional deficit. Key biomarkers include amyloid, tau, and increasingly neuroinflammation.
The traditional understanding held that amyloid was the first abnormality beginning in the brain, appearing up to two to three decades before clinical symptoms. Current understanding suggests inflammatory pathway changes may predate amyloid deposition. The sequence appears to be neuroimmunological changes, followed by amyloid, then tau, ultimately causing synaptic dysfunction where connections between nerve cells deteriorate, leading to cognitive changes over decades.
Dr. Devi has observed two pairs of siblings where one sibling in each pair has significant Alzheimer's pathology while the other does not, despite genetic comparability. In one notable case, a sibling with two copies of the APOE4 allele (which confers definite risk) has no amyloid in their 70s. The hypothesis suggests aggressive treatment of immunologic conditions may modulate the immune system and reduce Alzheimer's risk. This points to neuroinflammation as a critical frontier for prevention and treatment.
The relationship between shingles (varicella-zoster) vaccination and reduced dementia risk, as well as suppressive HSV treatment, supports the inflammatory pathway hypothesis. Gingival health and dementia also connect through inflammatory mechanisms, as inflamed gums create systemic inflammation affecting the brain.
Dr. Devi has maintained her practice on the Upper East Side for 26 years. Patients are referred by physicians, seek care directly after reading articles, or come through family and friend referrals. Most patients are highly functional professionals still working who want to maintain their careers. The practice has developed a niche evaluating physicians and other professionals.
Cognitive Reserve
High-functioning patients have extraordinary cognitive reserves that allow them to score normally on routine tests like the Mini Mental Status Exam or MoCA (scoring 28-30) even 10-15 years into their condition. Cognitive reserve refers to the brain's ability to maintain numerous connections and remain resilient to disease.
Comprehensive Evaluation Process
Evaluation includes meticulous general history covering immunologic conditions, past shingles exposure, and family history. Testing involves several hours of cognitive testing, brain electrophysiology to detect early slowing, transcranial Doppler for regional blood flow assessment, specialized MRI techniques evaluating hippocampus and parietal lobes for early differential changes, amyloid and tau PET scans when indicated, and DAT scans to assess dopamine levels for differential diagnosis. Laboratory testing includes Apo A, Apo B, inflammatory markers, APOE genotyping, and early-onset genetic screening when family history indicates.
Dr. Devi remains cautious about blood-based biomarkers for amyloid and phosphorylated tau, preferring standardization against both amyloid and tau rather than amyloid alone. Many individuals in their 70s and 80s have amyloid without developing Alzheimer's. For concerned patients, she typically performs either tau and amyloid PET scans or spinal tap. Spinal tap advantages include lower cost and ability to detect very early tau changes that traditional tau PET scans may miss. The disadvantage is patient reluctance, though many women have effectively had reverse spinal taps via epidural anesthesia.
Motivated patients traveling for evaluation can complete the full battery of tests over a 2-3 day period.
Determining pathology requires marrying symptoms, time course of symptom onset, patient age, comorbidities (hypertension, obesity, cholesterol), cerebrovascular disease (strokes and their locations), APOE4 allele copies, presenilin-1 mutations (100% associated with early-onset Alzheimer's), and cognitive scores across domains. A patient with 99th percentile overall intelligence but 10th percentile language scores raises concern for progressive language skill loss affecting occupational function.
Assessing Velocity of Decline
Single time-point assessment compares domain-specific performance against overall intelligence. Someone with 99th percentile overall ability but 10th percentile visual-spatial and language skills likely has declined significantly and may lose function rapidly in the coming year, warranting aggressive treatment. Reduced regional blood flow or EEG slowing in affected areas provides additional concerning indicators.
Mixed Pathology
Pure primary Alzheimer's is rare. Most patients have Alzheimer's plus cerebrovascular disease, hippocampal sclerosis, or TDP43 pathology. The contribution of each condition must be assessed. Memory-predominant impairment carries better prognosis than language-predominant impairment, with data showing different progression trajectories based on pathology location.
Avoiding Traditional Staging
Dr. Devi avoids traditional staging of Alzheimer's as reductionist and simplistic. Instead, she stages each functional domain separately, recognizing that a patient might be at stage zero in communication but stage three or four in memory, with different staging in language. This domain-specific approach better serves patients and families.
Difficulty remembering names of people met multiple times or names of places is one of the most common questions Dr. Devi encounters. Names represent inorganic, made-up information without inherent meaning. Modern life inundates people with names, whereas historically far fewer names needed to be remembered. Some speculate humans are evolutionarily adapted to remember approximately 150 names. Name recall difficulty is not considered a viable target for recovery efforts as people age, as it's an effort likely doomed to failure.
More concerning is difficulty recalling common nouns and finding words for objects or concepts, as this type of memory resides in brain regions handling factual information.
Names and episodic details (what was eaten for breakfast, the color of a jacket seen two days prior) are transient and time-stamped. The brain is evolutionarily designed to discard most daily micro-memories because retaining every exposure would impair function. This explains why forgetting names or recent episodes is normal and not necessarily indicative of pathology.
Women's life expectancy has nearly doubled in the past 150 years, moving from roughly 50–52 years to the late 70s or early 80s. Menopause now occurs well before the end of life; 150 years ago many women died around the time of menopause. Estrogen receptors colocalize in memory-critical regions such as the hippocampus, and estrogen promotes synaptic sprouting. Loss of estrogen after menopause or surgical menopause produces short-term memory deficits, executive dysfunction, and word-finding difficulty that mirror early Alzheimer's.
Women who undergo abrupt estrogen withdrawal can be misdiagnosed with Alzheimer's when the true cause is menopause-related cognitive impairment, which is treatable with hormone replacement or other interventions. Additional contributors to higher female prevalence include greater female survival after cardiovascular events, immunological differences (seen also in multiple sclerosis and lupus), and earlier menopause without hormone replacement therapy. Even after statistical adjustment for longevity, women remain at elevated risk.
Women with Alzheimer's more often present with depression, social withdrawal, and language problems; men more often present with aggression and agitation. Pathologic biomarkers (amyloid, tau) do not differ markedly by sex, but clinical presentation does.
Commercially available blood tests (Quest AD-Detect, Lumipulse, Precivity, C2N, Creyos AD) are standardized against amyloid PET. In community-dwelling adults, amyloid is present in approximately 25 % of those in their 70s, 30 %+ of those in their 80s, and 44 % of those in their 90s, many of whom remain asymptomatic. Because these tests are validated against a biomarker that is common in healthy aging, a positive blood test alone does not confirm clinical Alzheimer's.
Two diagnostic frameworks exist: the Alzheimer's Association criteria emphasize amyloid presence (biological diagnosis), while the International Working Group (largely European, with some U.S. centers) requires both amyloid and clinical symptoms (clinical-biological diagnosis). The latter approach aims to avoid labeling large numbers of “patients in waiting.”
A high-functioning man in his 70s received an abnormal AD-Detect blood test and was told he had Alzheimer's. Subsequent amyloid PET was negative. The episode illustrates the risk of diagnosing Alzheimer's from blood biomarkers alone.
Asymptomatic testing is generally avoided unless there is strong family history or genetic risk. A physician in her 50s with two APOE4 alleles and both parents confirmed to have Alzheimer's underwent CSF analysis showing low amyloid and borderline tau; she elected anti-amyloid therapy.
Two copies of APOE3 confer an approximate lifetime Alzheimer's risk of 6 % in men and 10–12 % in women. Two copies of APOE4 increase risk substantially (roughly 60 % relative increase versus wild-type) and are analogous to BRCA mutations in magnitude of effect, though not fully deterministic like PSEN1/PSEN2 or APP mutations.
The same physician patient started a GLP-1 agonist for weight reduction and a monoclonal antibody to remove emerging amyloid. Cognitive scores showed subtle language and memory weaknesses relative to her overall high functioning, supporting early intervention.
Three agents have been developed: aducanumab (approved July 2021, later withdrawn), lecanemab (biweekly IV), and donanemab (monthly IV). All clear amyloid plaque; aducanumab and donanemab also reduce tau. The FDA advisory committee recommended against aducanumab approval because plaque clearance did not consistently translate into clinically meaningful benefit, while serious adverse events (ARIA-E edema, ARIA-H hemorrhage) occurred in >40 % of patients and annual cost exceeded $50,000. The FDA overruled its advisory panel.
Because amyloid accumulates over decades, a very slow titration schedule (extending clearance to ~2 years) was implemented to reduce ARIA. In APOE4 homozygotes, standard protocols carry markedly elevated ARIA risk; the slow-titration approach reduced observed ARIA incidence to approximately 4 %. The FDA subsequently approved a slower titration schedule for donanemab after similar observations.
On the CDR Sum of Boxes (0–18 scale), active-drug versus placebo differences are small (0.3–0.4 points). Greater benefit appears when treatment begins before substantial tau pathology or synaptic loss. Whether anti-amyloid therapy can prevent disease in amyloid-positive, asymptomatic high-risk individuals remains under study.
When assessing new Alzheimer's drugs, a key question is whether amyloid removal is occurring and whether amyloid plays a meaningful role in the disease process. The same logic that applied to the first drug (Adicanumab) continues to apply to subsequent drugs like lecanemab and donanemab.
A personal litmus test for prescribing any new drug is whether one would take it themselves if they had Alzheimer's, given full knowledge of its effects. This threshold was met for Adicanumab, leading to its use in patients.
Adicanumab was withdrawn from the market due to the requirement for post-approval monitoring, which became financially unfeasible for the company rather than due to lack of efficacy or safety concerns per se.
The drugs themselves cost approximately $26,000 annually. Administration fees vary significantly: institutional settings can charge as much as $10,000 per infusion, while infusion centers may charge around $400. Additional costs include required MRIs and amyloid imaging.
Insurance companies often refuse to reimburse patients for lower starting doses of lecanemab intended to titrate up gradually, even when this approach is used to reduce risk of ARIA (amyloid-related imaging abnormalities). Patients must pay out of pocket for safer titration protocols with lecanemab.
Donanemab's titration schedule (350 mg to 700 mg to 1050 mg to 1400 mg) allows more flexibility in maintaining lower doses without triggering insurance scrutiny.
Patients with APOE4 genotypes face elevated risk of ARIA. An APOE 3/4 genotype increases susceptibility compared to 3/3, and APOE 4/4 carries the highest risk for edema and hemorrhage in response to these drugs.
One patient with APOE 4/4 developed severe ARIA on just 3 mg/kg of lecanemab, raising concerns about the standard 10 mg/kg starting dose. Another 51- or 52-year-old patient developed significant bilateral ARIA on 3 mg/kg of lecanemab after six doses (approximately three months) and continued to show ARIA in different areas.
Monoclonal antibodies enter the brain and clear amyloid from brain tissue but also remove amyloid from the tunica media (middle layer) of small brain arteries. This disrupts the arterial lining, causing initial leakage of fluid (edema, or ARIA-E) and potentially progressing to actual blood extravasation (hemorrhage, or ARIA-H) when the vessel lining tears. Large disruptions can cause massive brain bleeds, with reported deaths particularly in patients on blood thinners such as those prescribed for atrial fibrillation.
Over five years of using monoclonal antibodies (since 2021), the incidence of ARIA has been approximately 4%, but symptomatic ARIA has occurred in only one case. Most ARIA is discovered on MRI rather than through clinical symptoms. One patient on Adicanumab (APOE 4/4, early 60s) developed significant ARIA-E with microhemorrhages at month 18-19 on 8 mg/kg dosing but remained asymptomatic even on careful neurologic examination.
When ARIA is detected, dosing is adjusted. One approach involves reducing the dose (e.g., from 8 mg/kg to 6 mg/kg) and then re-titrating upward. For patients with cerebral amyloid angiopathy (CAA), who can develop spontaneous ARIA-E, treatment with steroids is used. In refractory cases, such as a young APOE 4/4 patient on 3 mg/kg lecanemab, prophylactic low-dose steroids are given before each subsequent infusion to control ARIA-E.
Current trials are open-label with no placebo or standard-care comparator arms. An ideal but likely cost-prohibitive study would test a low-and-slow early intervention approach in high-risk patients (APOE 4/4) in their 50s or 60s who are 5-10 years from clinical disease, asking whether this strategy bends the disease trajectory. In florid dementia, high-dose monoclonal antibodies do not appear to meaningfully alter disease course, and the risk-benefit ratio is unfavorable for APOE 4/4 patients at advanced stages.
Chronic diseases like atherosclerosis require prolonged treatment to demonstrate benefit; short-duration interventions are insufficient. The high cost of monoclonal antibodies limits broader access and the ability to conduct longer-term studies in appropriate populations.
Future agents are expected to reduce the risk of edema and hemorrhage. Oral (pill) formulations and home administration are anticipated. Subsequent generations of these drugs are expected to improve on current limitations, as has occurred with other drug classes such as GLP-1 agonists and statins.
A woman in her 70s with functional ability at the 70th percentile developed Alzheimer's. After a spinal tap confirmed amyloid and tau pathology, she was treated with lecanemab, cleared amyloid, and subsequently showed no detectable tau on a tau PET scan. Clinically she has done remarkably well. A spinal tap is pending to confirm whether pathology has been fully cleared.
An identical twin with Alzheimer's on monoclonal antibodies (initially Adicanumab, then donanemab) performed substantially better than her co-twin in a facility. This patient also had rheumatic heart disease requiring an artificial valve and was on Coumadin; she tolerated monoclonal antibody therapy without side effects and cleared her amyloid.
Early diagnosis and treatment can change the trajectory of cognitive health in some patients, though response varies, possibly due to differences in immune function.
Prior to monoclonal antibodies and continuing today, treatment involves combination therapy modeled on the HIV/AIDS approach: cholinesterase inhibitors (donepezil, galantamine), memantine (NMDA receptor antagonist that reduces signal-to-noise ratio in neurotransmission and may prevent apoptosis), and, depending on the patient, belimumab or other immune-modifying treatments. Comorbidity management is emphasized. Ventriculoperitoneal shunting is used when hydrocephalus is present.
Since 2008, transcranial magnetic stimulation (TMS) has been used to maintain neuronal connectivity and network function. TMS stimulates a small cortical area (~1 cm²) under the coil, activating connected circuits. It is applied using neuronavigation guided by the patient's MRI, targeting the dorsolateral prefrontal cortex, Broca's area, precuneus (for parietal and visuospatial function), and in some patients the auditory Wernicke's area. TMS is used off-label for dementia (approved only for depression and certain electrodiagnostic purposes in the US) and has been particularly helpful for language problems.
GLP-1 agonists are believed to offer benefit for dementia risk reduction beyond weight loss and improved metabolic health, potentially through anti-inflammatory pathways. Metformin may also confer benefit. Obesity rates in the United States are declining due to GLP-1 use, which may have downstream effects on brain diseases linked to obesity, cardiovascular disease, and diabetes.
Alzheimer's disease almost never occurs in isolation. Autopsy studies show that 98-99% of Alzheimer's patients have concomitant primary brain pathology, most commonly vascular disease. Pure primary vascular dementia is rarer than expected given the prevalence of vascular brain changes with age. White matter changes once considered benign are now recognized as progressive, interrupting brain connectivity and reducing resilience to pathology.
Treatment of vascular contributions is rigorous and includes statins. For patients with multiple strokes due to atrial fibrillation or other cardiac sources, a Watchman device is recommended to allow discontinuation of anticoagulants (Eliquis, Xarelto), reducing fall-related bleeding risk in patients with dementia. The same strategy enables some patients previously excluded from monoclonal antibodies due to anticoagulation to safely discontinue anticoagulants and start antibody therapy.
Approximately 40% of Alzheimer's patients eventually develop some Lewy body pathology, and 30-40% of Lewy body patients have Alzheimer's pathology; the conditions frequently coexist. Many patients with Lewy body disease are misdiagnosed with Parkinson's disease and treated with levodopa/carbidopa or dopamine agonists (e.g., Mirapex), which can worsen confusion and fail to improve symptoms.
Diagnosis of Lewy body disease includes workup for Alzheimer's biomarkers due to high comorbidity. Lewy body-specific biomarkers include DaT scans, skin biopsies for alpha-synuclein, and CSF analysis for alpha-synuclein. The notion that Lewy body disease is rapidly progressive with death in 5-6 years is incorrect; many patients respond well to treatment, sometimes better than Alzheimer's patients, and life expectancy is not markedly different.
APOE4 increases risk for Lewy body disease, though less dramatically than for Alzheimer's, likely due to impaired clearance of pathologic proteins. Alpha-synuclein pathology is shared between Lewy body disease and Parkinson's disease. The distinction is largely temporal: motor symptoms for less than one year (some say two years) followed by cognitive symptoms indicates Lewy body disease, whereas longer intervals indicate Parkinson's disease dementia. In Lewy body disease, alpha-synuclein pathology is more widespread than the basal ganglia-predominant distribution seen in Parkinson's.
A clinical clue is that rest tremor (classic pill-rolling tremor) has never been observed as an initial presentation in Lewy body disease patients, despite the requirement for motor symptoms in the diagnosis.
DAT scans show classic patterns in Lewy body disease that are absent in Parkinson's disease, though the distinction is not as rigorous as desired. The clinical differentiation matters because Parkinson's disease is treated with medications that increase brain dopamine levels, while adding dopamine in Lewy body disease can cause serious negative side effects including psychosis and worsening existing psychosis.
Lewy body disease is diagnosed clinically by the presence of parkinsonian motor features, fluctuating consciousness, cognitive impairment, and often visual hallucinations. Patients with Lewy body disease maintain insight into their visual hallucinations. One patient described knowing she was not in her house despite others insisting she was, and recognizing that her perception did not align with reality. Alzheimer's patients rarely demonstrate this level of insight during hallucinations and delusions.
A patient with Lewy body disease reported calling the police after seeing people on the street, stating she knew they were not real because she had experienced this before, yet they looked completely real to her. Auditory hallucinations are rare in Lewy body disease; the clinician reported never having a patient with auditory hallucinations in her practice.
Fewer widespread diagnostic tools exist for alpha-synuclein compared to amyloid beta. Skin biopsies are now used to detect alpha-synuclein and represent a relatively easy procedure. The protein travels along neural pathways, so skin biopsies actually sample small cutaneous nerves rather than skin itself. Punch biopsies are taken from the neck, knee, and further down the body to assess how much synuclein is present at each level. Greater synuclein further from the central nervous system indicates more widespread disease.
Skin biopsies help distinguish synuclein-related motor disorders from other conditions that can mimic them. The biopsies provide information about sensory nerves, which represent relatively small cortical real estate. Visual hallucinations are used to infer occipital lobe involvement in clinical assessment.
For dementia with Lewy bodies, patients are always worked up for Alzheimer's disease due to high comorbidity between the two conditions. A DAT scan can reveal abnormalities in the basal ganglia consistent with Lewy body disease, but biopsy confirmation is needed to verify alpha-synuclein as the driving pathology.
One of the most important treatment steps is discontinuing Parkinson's medications in patients with Lewy body disease. This can be difficult because patients often enjoy the dopamine high from these medications. A patient in her seventies had been prescribed three tablets of levodopa-carbidopa three times daily despite a negative DAT scan and no rest tremor. She reported feeling down before each dose and described the pills as resetting her through the dopamine effect.
The patient had essential tremor rather than Parkinson's tremor, yet had been treated at an academic institution for presumed Parkinson's disease. Getting patients off these medications represents a significant clinical challenge.
Lewy body disease typically occurs in slightly younger patients than other dementias. Vascular risk factors increase risk for Lewy body disease. Alzheimer's disease increases risk for Lewy body disease. Parkinson's disease increases risk for Lewy body disease. Essential tremor also increases risk because it exists on a spectrum that may morph into Lewy body disease.
It remains unclear whether these conditions directly increase risk or whether their presence demonstrates underlying factors that drive multiple conditions. Metabolic dysfunction is considered causally related to Alzheimer's risk, leading to aggressive targeting of hypertension, dyslipidemia, and insulin resistance. The same level of conviction does not yet exist for Lewy body dementia due to insufficient data.
Anything beneficial for the heart is considered beneficial for the brain regardless of underlying brain pathology. More robust data sets are needed for Lewy body disease.
Lewy body disease shows a slight male predominance, possibly because more men have Parkinson's disease. Menopause-related cognitive impairment is a recognized clinical entity. For women with this condition who have no contraindications, estrogen is recommended. When estrogen-sensitive breast cancer is being actively treated, estrogen is not given.
Targeted brain exercises are effective for menopause-related cognitive impairment. The brain demonstrates learned non-use, where disuse leads to dysfunction. Constraint-induced movement therapy principles apply here: forcing use of affected cognitive areas through targeted exercises, even once weekly, can produce dramatic functional recovery.
Cholinesterase inhibitors can be used because the underlying mechanism involves loss of acetylcholine in the nucleus basalis. A double-blind placebo-controlled trial of donepezil versus placebo in 42 menopausal women with cognitive impairment showed a trend toward improvement in the donepezil group. Transcranial magnetic stimulation also appears helpful.
Patients on anti-estrogen therapies for breast or ovarian cancer, such as anastrozole, may experience severe cognitive impairment and request to discontinue treatment regardless of personal risk. A patient who underwent mastectomies, oophorectomies, and hysterectomy for breast cancer with genetic risk factors developed devastating cognitive effects after hormone replacement therapy was discontinued during chemotherapy. She was functionally debilitated and essentially bedridden in her fifties.
After discussions with multiple physicians, she was restarted on hormone therapy with remarkable and rapid cognitive recovery. Some patients prefer to accept cancer recurrence risk rather than experience ongoing cognitive decline and functional inability. The clinician agrees that aggressive use of aromatase inhibitors for DCIS may cause harm without clear benefit given the small risk being mitigated over five years for a precancerous lesion.
A 20- to 21-year-old college student presented with six months of complete brain fog preventing her from functioning at a good university. Her estrogen level measured 22 pg/dL with normal FSH and LH, suggesting primary ovarian failure of unknown cause. Low-dose oral contraceptive was recommended to allow her to complete school while further evaluation proceeded.
Transdermal estrogen via gel or patch is preferred over oral estrogen due to lower risk of strokes and venous clots.
Ten years prior, the clinician never believed patients with Alzheimer's could improve. Even before monoclonal antibodies existed, patients improved with treatment, which contradicted conventional teaching that Alzheimer's involves inexorable decline. Before biomarkers and spinal taps became available in 2007, improvement was attributed to possible misdiagnosis. Approximately 30% of patients in Alzheimer's drug trials lacked Alzheimer's pathology and were misdiagnosed clinically.
After gaining biomarker capability in 2007, it became clear that Alzheimer's patients could improve. Some recovered with simple interventions like brain exercises. It took an additional five to eight years to fully accept this possibility because the teaching that decline was inevitable was so deeply ingrained. The clinician has specialized in this field since 1994.
For preventing Alzheimer's disease, AI for early detection of changes in thinking patterns is expected to have the biggest impact, alongside medication cocktails targeting inflammation first and then pathology in high-risk patients. For treatment, targeted neuromodulation will be important in addition to drugs that reduce pathology.
Drugs targeting neuroinflammation exist in the pipeline. Intravenous immunoglobulin was used in Alzheimer's patients diagnosed by spinal tap analysis, with two patients becoming plaque-negative. One remained stable for 17 years; the other remains stable. APOE4 carriers were far more likely to benefit from IVIG.
The hope is that within five years, clinical trials will incorporate better risk identification, stratification, and tailored treatments rather than applying uniform approaches to heterogeneous populations. Alzheimer's disease is the most heterogeneous condition encountered, with each patient having their own individual version of the disease. Identical twins with Alzheimer's can show dramatically different disease risk and timing despite identical genetics and shared environment, with one twin sometimes developing illness 10 to 15 years after the other. Inflammation, epigenetics, and individual brain differences drive these variations, necessitating nuanced approaches.
Keep Peter Attia MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
